Taken together, this study provides a novel theranostic approach through removing Cu in tumor to decrease PD-L1 expression, laying the foundation for clinical trials to evaluate copper nanodeprivator as immune checkpoint inhibitors. This evidence concerns the gene CD274 and neoplasm.